Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Stopped early · Early Phase 1

Conditions studied: Hemangioblastomas, Von Hippel Lindau Disease

In brief

Von Hippel-Lindau (VHL) disease is an inherited syndrome manifested by a variety of benign and malignant tumors. Hemangioblastomas are the most common lesion associated with VHL disease affecting 60-84% of patients with a mean age at diagnosis of 29 years. Standard treatment for this disease is by surgery or radiotherapy. No approved systemic therapy yet exists. Patients with VHL have an increased growth factor production, specifically vascular endothelial growth factor (VEGF), resulting in angiogenesis (growth of blood vessels). Studies show that Bevacizumab inhibits the growth of VEGF protein and will block the VEGF-driven angiogenesis and result in stabilization and regression of hemangioblastomas in VHL disease patients. The dose of bevacizumab will be 10 mg/kg every two weeks for up to 6 months.

Key facts

Study ID

NCT01015300

Run by

Dartmouth-Hitchcock Medical Center

People needed

1

Starts

2009-12-01

Expected to finish

2012-04-01

Last updated by the study team

2012-05-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• One or more CNS hemangioblastomas not amendable to surgical resection or recurrent post resection
• Confirmed diagnosis of von-Hippel-Lindau disease
• No prior treatment with VEGF inhibitors
• Index hemangioblastomas lesion at least 5mm on MRI
• No major bleeding event from hemangioblastoma within 90 days
• KPS > or equal to 60%
• Age > or equal to 18 years

You may not qualify if…

• Prior treatment with VEGF inhibitors
• Major bleeding event from hemangioblastoma within 90 days
• Inability to comply with study and/or follow up procedures
• Life expectancy of less than 12 weeks
• Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study other than a Genentech sponsored bevacizumab cancer study
• Active malignancy will be permissible if treating physician deems that concurrent administration of bevacizumab is not contraindicated and that the patient would be able to complete with the other parameters of the protocol

Where it is running

• Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.